ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye

Gerçek yaşamda, çevresel maruziyetlerin de etkilediği rinit ve astım mültimorbidite durumlarında, dijitalleşmiş ve kişiye odaklanan tedaviler içinbütünleştirilmiş tedavi yollarının değerlendirilmesi önerilmektedir. Gerçek yaşamdaki bu durum mültisipliner bir yaklaşımla basamaklandırılıp,rehberilerinde ülkelerdeki gereksinimlere göre değiştilmesini gerektirebilir. Allerjik rinitte hem farmakoterapi hem immünoterapi açısından acilyeni yaklaşımlara ihtiyaç olduğu görülmüştür. 3. Aralık 2018’de Paris’te bir toplantı yapılmış ve iki ayrı belge hazırlanmıştır. Bu yayında bunlaraait bir özet sunulup, ülkeye ve sağlık sistemine uygun kullanımın çerçevesi oluşturulmak istenmiştir.

Anahtar Kelime:

2019 ARIA Care Pathways for Allergic Rhinitis-Turkey

Öz:

The evaluation of real-life integrated care pathways (ICPs) was recommended for digitally enabled, integrated, person-centered care for rhinitis and asthma multimorbidity embedding environmental exposure. ICPs are structured multidisciplinary care plans detailing key steps of patient care. They promote the translation of guideline recommendations into local protocols and their application to clinical practice. In allergic rhinitis, there is an urgent need to develop next-generation guidelines for pharmacotherapy and ICPs for allergen immunotherapy. A meeting was held in Paris on December 3, 2018, during which two separate documents were produced. An executive summary is presented in this article, which will be customized in different countries or regions in order to adjust the conclusions of the papers for local use and health systems.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45. [CrossRef]
2. Bousquet J, Anto JM, Annesi-Maesano I, et al. POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clin Transl Allergy 2018;8:36. [CrossRef]
3. Bousquet J, Schunemann HJ, Togias A, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy 2019;9:44. [CrossRef]
4. Palmer K, Marengoni A, Forjaz MJ, et al. Multimorbidity care model: Recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Health Policy 2018;122:4-11. [CrossRef]
5. Bousquet J, Addis A, Adcock I, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014;44:304-23. [CrossRef]
6. Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy 2019;9:16. [CrossRef]
7. Hellings PW, Borrelli D, Pietikainen S, et al. European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). Clin Transl Allergy 2017;7:49. [CrossRef]
8. Bédard A, Basagaña X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol 2019;144:135-43. [CrossRef]
9. Civelek E, Yavuz ST, Boz AB, et al. Epidemiology and burden of rhinitis and rhinoconjunctivitis in 9- to 11-year-old children. Am J Rhinol Allergy 2010;24:364-70. [CrossRef]
10. Türk Toraks Derneği Astım Tanı ve Tedavi Rehberi. 2016 Güncellemesi. Turkish Thoracic J 2016; 17(Suppl): 1-74.
11. Gurkan F, Davutoglu M, Bilici M, et al. Asthmatic children and risk factors at a province in the southeast of Turkey. Allergol Immunopathol (Madr) 2002;30:25-9.v [CrossRef]
12. Kocabas CN, Civelek E, Sackesen C, et al. Burden of rhinitis in children with asthma. Pediatr Pulmonol 2005;40:235-40. [CrossRef]
13. Gemicioglu B, Bayram H, Cimrin A, et al. Asthma control and adherence in newly diagnosed young and elderly adult patients with asthma in Turkey. J Asthma 2019;56:553-61. [CrossRef]
14. Civelek E, Soyer OU, Gemicioglu B, Sekerel BE. Turkish physicians' perception of allergic rhinitis and its impact on asthma. Allergy 2006;61:1454-8. [CrossRef]
15. Yorgancioğlu A, Kalayci O, Kalyoncu AF, et al. Allergic rhinitis and its impact on asthma update (ARIA 2008). The Turkish perspective. Tuberk Toraks 2008;56:224-31.
16. Yorgancıoğlu A, Özdemir C, Kalaycı Ö, et al. ARIA (Allergic Rhinitis and its Impact on Asthma) achievements in 10 years and future needs. Tuberk Toraks 2012;60:92-7. [CrossRef]
17. Yorgancıoğlu AA, Kalaycı Ö, Cingi C, et al. ARIA 2016 executive summary: integrated care pathways for predictive medicine across the life cycle. Tuberk Toraks 2017;65:32-40. [CrossRef]
18. Yorgancıoğlu AA, Gemicioğlu B, Kalaycı Ö, et al. MASK (Mobile Airways Sentinel networK) in Turkey-the ARIA integrated mobile solution for allergic rhinitis and asthma multimorbidity. Tuberk Toraks 2018;66:176-81. [CrossRef]
19. Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? J Allergy Clin Immunol Pract 2016;4:682-8. [CrossRef]
20. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med 2016;375:2293-7. [CrossRef]
21. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76. [CrossRef]
22. Brozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision. J Allergy Clin Immunol 2017;140:950-8. [CrossRef]
23. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol 2017;119:489-511. [CrossRef]
24. Bousquet J, Devillier P, Anto JM, et al. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy 2018;73:1622-31. [CrossRef]
25. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy 2018;73:1763-74. [CrossRef]
26. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol 2016;138:367-74. [CrossRef]
27. Courbis AL, Murray RB, Arnavielhe S, et al. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy 2018;48:1640-53. [CrossRef]
28. Horak F, Bruttmann G, Pedrali P, et al. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung 1988;38:124-8.
29. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and flticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105:168-73. [CrossRef]
30. Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001;161:2581-7. [CrossRef]
31. Glacy J, Putnam K, Godfrey S, et al. Treatments for Seasonal Allergic Rhinitis. AHRQ Comparative Effectiveness Reviews. Rockville (MD) 2013.
32. “Draft Guidance for Industry: Allergic Rhinitis: Clinical Development Programs for Drug Products”, Food and Drug Administration, CDER. Available from: URL: http://wwwfdagov/cder/guidance/indexhtm. 2000.
33. Allergic Rhinitis: developping drug products for treatment. Guidance for industry.U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2016 Clinical/Medical Revision 1. Available from: URL: https://wwwfdagov/downloads/drugs/guidances/ucm071293pdf. 2016.
34. Katial RK, Salapatek AM, Patel P. Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? Allergy Asthma Proc 2009;30:595-604. [CrossRef]
35. Patel P, D'Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 2007;21:499-503. [CrossRef]
36. Bousquet J, Meltzer EO, Couroux P, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract 2018;6:1726-32. [CrossRef]
37. Patel P, Roland PS, Marple BF, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 2007;137:918-24. [CrossRef]
38. Salapatek AM, Lee J, Patel D, et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc 2011;32:221-9. [CrossRef]
39. Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and effiacy. Curr Med Res Opin 2006;22:151-7. [CrossRef]
40. Zieglmayer P, Zieglmayer R, Bareille P, et al. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin 2008;24:1833-40. [CrossRef]
41. Murdoch RD, Bareille P, Ignar D, et al. The improved effiacy of a fied-dose combination of flticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy 2015;45:1346-55. [CrossRef]
42. Sleurs K, Seys S, Bousquet J, et al. Mobile health tools for the management of chronic respiratory diseases. Allergy 2019;74:1292-306. [CrossRef]
43. Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy 2016;6:47. [CrossRef]
44. Menditto E, Guerriero F, Orlando V, et al. Self-Assessment of Adherence to Medication: A Case Study in Campania Region CommunityDwelling Population. J Aging Res 2015;2015:682503. [CrossRef]
45. Bonini M. Electronic health (e-Health): emerging role in asthma. Curr Opin Pulm Med 2017;23:21-6. [CrossRef]
46. Pizzulli A, Perna S, Florack J, et al. The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2014;44:1246-54. [CrossRef]
47. Price D, Scadding G, Ryan D, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy 2015;5:39. [CrossRef]
48. Bousquet J, Murray R, Price D, et al. The allergic allergist behaves like a patient. Ann Allergy Asthma Immunol 2018;121:741-2. [CrossRef]
49. Patel P, Patel D, Kunjibettu S, et al. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ear Nose Throat J 2008;87:340-53. [CrossRef]
50. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1-84. [CrossRef]
51. Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013;68:1102-16. [CrossRef]
52. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017;47:856-89. [CrossRef]
53. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with flticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9 e10. [CrossRef]
54. Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc 2013;34:301-11. [CrossRef]
55. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg 2015;152:197-206. [CrossRef]
56. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg 2015;152(1 Suppl):S1-43.
57. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy 2018;8:25. [CrossRef]
58. Church MK, Maurer M, Simons FE, et al. Risk of fist-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459-66. [CrossRef]
59. Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol 2017;28:728-45. [CrossRef]
60. Bonertz A, Roberts G, Slater JE, et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy 2018;73:816-26. [CrossRef]
61. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018;73:765-98.[CrossRef]
62. Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy 2019; 74:2087-102. [CrossRef]
63. Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specifi immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNOKHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282-319. [CrossRef]
64. Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018;73:739- 43. [CrossRef]
65. Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy 2018;73:165-77. [CrossRef]
66. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors inflence its decisions? A binary choice analysis. Health Econ 2004;13:437-52. [CrossRef]
67. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:1-322. [CrossRef]
68. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160.
69. Larenas-Linnemann DES, Antolin-Amerigo D, Parisi C, et al. National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II. Allergy 2018;73:664-72. [CrossRef]
70. Bonertz A, Roberts GC, Hoefnagel M, et al. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy 2018;73:64-76. [CrossRef]
71. Committee for medicinal products for human use (CPMP). Guideline on allergen products: production and quality issues. EMEA/ CHMP/BWP/304831/2007. London, 20 November 2008.
72. Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 2016;9:33. [CrossRef]
73. Bachert C, Larche M, Bonini S, et al. Allergen immunotherapy on the way to product-based evaluation-a WAO statement. World Allergy Organ J 2015;8:29. [CrossRef]
74. Wheatley L, Wood R, Nadeau K, et al. Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy. An NIAID/AHRQ workshop. J Allergy Clin Immunol 2019;143:1711-26. [CrossRef]
75. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401-5. [CrossRef]
76. Didier A, Malling HJ, Worm M, et al. Optimal dose, effiacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45. [CrossRef]
77. Nelson H, Blaiss M, Nolte H, et al. Effiacy and safety of the SQstandardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013;68:252-5. [CrossRef]
78. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confimation of disease modifiation 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25. [CrossRef]
79. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-74. [CrossRef]
80. Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132:93-8. [CrossRef]
81. Baiardini I, Puggioni F, Menoni S, et al. Patient knowledge, perceptions, expectations and satisfaction on allergen-specifi immunotherapy: a survey. Respir Med 2013;107:361-7. [CrossRef]
82. Nam YH, Lee SK. Physician's recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy. Patient Prefer Adherence 2017;11:381-7. [CrossRef]
83. Chivato T, Alvarez-Calderon P, Panizo C, et al. Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain. Clin Mol Allergy 2017;15:1. [CrossRef]
84. Skoner DP, Blaiss MS, Dykewicz MS, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients' experience with allergen immunotherapy. Allergy Asthma Proc 2014;35:219-26. [CrossRef]
85. Pitsios C, Dietis N. Ways to increase adherence to allergen immunotherapy. Curr Med Res Opin 2019;35:1027-31. [CrossRef]
86. Bender BG, Lockey RF. Solving the Problem of Nonadherence to Immunotherapy. Immunol Allergy Clin North Am 2016;36:205-13. [CrossRef]
87. Bachert C, Gräfi-von-Strachwitz-Helmstatt K. Zur Diskussion gestellt: Der Arzt und die Spezifiche Immuntherapie im Spannungsfeld von Leitlinie, Wirtschaftlichkeit und Medizinrecht. Allergologie 2016;39:381-8. [CrossRef]
88. Kuehl BL, Abdulnour S, O'Dell M, Kyle TK. Understanding the role of the healthcare professional in patient self-management of allergic rhinitis. SAGE Open Med 2015;3:2050312115595822. [CrossRef]
89. Bosnic-Anticevich S, Kritikos V, Carter V, et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fied-dose combination therapy in Australia. J Asthma 2018;55:684-94. [CrossRef]
90. Bosnic-Anticevich S, Costa E, Menditto E, et al. ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project. Allergy 2019;74:1219-36.
91. Jutel M, Papadopoulos NG, Gronlund H, et al. Recommendations for the allergy management in the primary care. Allergy 2014;69:708-18. [CrossRef]
92. Finlay I, Egner W. Allergy--will we ever meet the unmet need? J R Soc Med 2010;103:430-1. [CrossRef]
93. Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy 2017;72:1297-305. [CrossRef]
94. Pinnock H, Thomas M, Tsiligianni I, et al. The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. Prim Care Respir J 2010;19(Suppl 1):S1-20. [CrossRef]
95. Shehata Y, Ross M, Sheikh A. Undergraduate allergy teaching in a UK medical school: comparison of the described and delivered curriculum. Prim Care Respir J 2007;16:16-21. [CrossRef]
96. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. EAACI, Immunotherapy Task Force. Standards for practical allergen-specifi immunotherapy. Allergy 2006;61(Suppl 82):1-20. [CrossRef]
97. Landi M, Meglio P, Praitano E, et al. The perception of allergenspecifi immunotherapy among pediatricians in the primary care setting. Clin Mol Allergy 2015;13:15. [CrossRef]
98. Canonica GW, Bachert C, Hellings P, et al. Allergen Immunotherapy (AIT): a prototype of Precision Medicine. World Allergy Organ J 2015;8:31. [CrossRef]
99. Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO - ARIA - GA(2)LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 2013;6:17. [CrossRef]
100. Lee J, Kronborg C, O'Hehir RE, Hew M. Who's at risk of thunderstorm asthma? The ryegrass pollen trifecta and lessons learnt from the Melbourne thunderstorm epidemic. Respir Med 2017;132:146-8. [CrossRef]
101. O'Hehir RE, Varese NP, Deckert K, et al. Epidemic Thunderstorm Asthma Protection with Five-Grass Pollen Tablet Sublingual Immunotherapy: A Clinical Trial. Am J Respir Crit Care Med 2018;198:126-8. [CrossRef]
102. Pitsios C, Demoly P, Bilo MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015;70:897-909. [CrossRef]
103. Global Strategy for Asthma Management and Prevention (2018 update). Available from: wms-GINA-2018-report-V13-002pdf. 2018.
104. Amaral R, Fonseca JA, Jacinto T, et al. Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007-2012. Clin Transl Allergy 2018;8:13. [CrossRef]
105. Summary of product characteristics. Acarizax 12 SQ-HDM oral lyophilisate. European Medicines Agency. Available from: URL: https://mricts-mrpeu/Human/Downloads/DE_H_1947_001_FinalSPCpdf. 2016.
106. Masuyama K, Okamoto Y, Okamiya K, et al. Effiacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy 2018;73:2352-63. [CrossRef]
107. Penagos M, Eifan AO, Durham SR, Scadding GW. Duration of Allergen Immunotherapy for Long-Term Effiacy in Allergic Rhinoconjunctivitis. Curr Treat Options Allergy 2018;5:275-90. [CrossRef]
108. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018;141:529-38. [CrossRef]
109. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6. [CrossRef]
110. Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: A systematic review and metaanalysis. Pediatr Allergy Immunol 2017;28:18-29. [CrossRef]
111. Bozek A, Kolodziejczyk K, Kozlowska R, Canonica GW. Evidence of the effiacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial. Clin Transl Allergy 2017;7:43. [CrossRef]
112. Bousquet J, Arnavielhe S, Bedbrook A, et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy 2018;73:505-10. [CrossRef]
113. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69:854-67. [CrossRef]

APA	yorgancıoglu a, Gemicioglu B, Cingi C, KALAYCI O, Kalyoncu A, Bachert C, Hellings P, Pfaar O, Schünemann H, Wallace D, Bedbrook A, Czarlewski W, Bousquet J (2020). ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. , 122 - 133. 10.5152/TurkThoracJ.2019.19084
Chicago	yorgancıoglu arzu,Gemicioglu Bilun,Cingi Cemal,KALAYCI Omer,Kalyoncu Ali Fuat,Bachert Claus,Hellings Peter,Pfaar Oliver,Schünemann Holger,Wallace Dana,Bedbrook Anna,Czarlewski Wienczyslawa,Bousquet Jean ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. (2020): 122 - 133. 10.5152/TurkThoracJ.2019.19084
MLA	yorgancıoglu arzu,Gemicioglu Bilun,Cingi Cemal,KALAYCI Omer,Kalyoncu Ali Fuat,Bachert Claus,Hellings Peter,Pfaar Oliver,Schünemann Holger,Wallace Dana,Bedbrook Anna,Czarlewski Wienczyslawa,Bousquet Jean ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. , 2020, ss.122 - 133. 10.5152/TurkThoracJ.2019.19084
AMA	yorgancıoglu a,Gemicioglu B,Cingi C,KALAYCI O,Kalyoncu A,Bachert C,Hellings P,Pfaar O,Schünemann H,Wallace D,Bedbrook A,Czarlewski W,Bousquet J ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. . 2020; 122 - 133. 10.5152/TurkThoracJ.2019.19084
Vancouver	yorgancıoglu a,Gemicioglu B,Cingi C,KALAYCI O,Kalyoncu A,Bachert C,Hellings P,Pfaar O,Schünemann H,Wallace D,Bedbrook A,Czarlewski W,Bousquet J ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. . 2020; 122 - 133. 10.5152/TurkThoracJ.2019.19084
IEEE	yorgancıoglu a,Gemicioglu B,Cingi C,KALAYCI O,Kalyoncu A,Bachert C,Hellings P,Pfaar O,Schünemann H,Wallace D,Bedbrook A,Czarlewski W,Bousquet J "ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye." , ss.122 - 133, 2020. 10.5152/TurkThoracJ.2019.19084
ISNAD	yorgancıoglu, arzu vd. "ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye". (2020), 122-133. https://doi.org/10.5152/TurkThoracJ.2019.19084

APA	yorgancıoglu a, Gemicioglu B, Cingi C, KALAYCI O, Kalyoncu A, Bachert C, Hellings P, Pfaar O, Schünemann H, Wallace D, Bedbrook A, Czarlewski W, Bousquet J (2020). ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. Turkish Thoracic Journal, 21(2), 122 - 133. 10.5152/TurkThoracJ.2019.19084
Chicago	yorgancıoglu arzu,Gemicioglu Bilun,Cingi Cemal,KALAYCI Omer,Kalyoncu Ali Fuat,Bachert Claus,Hellings Peter,Pfaar Oliver,Schünemann Holger,Wallace Dana,Bedbrook Anna,Czarlewski Wienczyslawa,Bousquet Jean ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. Turkish Thoracic Journal 21, no.2 (2020): 122 - 133. 10.5152/TurkThoracJ.2019.19084
MLA	yorgancıoglu arzu,Gemicioglu Bilun,Cingi Cemal,KALAYCI Omer,Kalyoncu Ali Fuat,Bachert Claus,Hellings Peter,Pfaar Oliver,Schünemann Holger,Wallace Dana,Bedbrook Anna,Czarlewski Wienczyslawa,Bousquet Jean ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. Turkish Thoracic Journal, vol.21, no.2, 2020, ss.122 - 133. 10.5152/TurkThoracJ.2019.19084
AMA	yorgancıoglu a,Gemicioglu B,Cingi C,KALAYCI O,Kalyoncu A,Bachert C,Hellings P,Pfaar O,Schünemann H,Wallace D,Bedbrook A,Czarlewski W,Bousquet J ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. Turkish Thoracic Journal. 2020; 21(2): 122 - 133. 10.5152/TurkThoracJ.2019.19084
Vancouver	yorgancıoglu a,Gemicioglu B,Cingi C,KALAYCI O,Kalyoncu A,Bachert C,Hellings P,Pfaar O,Schünemann H,Wallace D,Bedbrook A,Czarlewski W,Bousquet J ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. Turkish Thoracic Journal. 2020; 21(2): 122 - 133. 10.5152/TurkThoracJ.2019.19084
IEEE	yorgancıoglu a,Gemicioglu B,Cingi C,KALAYCI O,Kalyoncu A,Bachert C,Hellings P,Pfaar O,Schünemann H,Wallace D,Bedbrook A,Czarlewski W,Bousquet J "ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye." Turkish Thoracic Journal, 21, ss.122 - 133, 2020. 10.5152/TurkThoracJ.2019.19084
ISNAD	yorgancıoglu, arzu vd. "ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye". Turkish Thoracic Journal 21/2 (2020), 122-133. https://doi.org/10.5152/TurkThoracJ.2019.19084